Date:3/16/2010

"I am delighted to be working with SpineMark. Their specialized dedication to clinical research in spine, their relationships, and their ability to manage various aspects of the US clinical trial process makes them a perfect fit for our study," explains Dr. Geoffrey Andrews, CEO of Ranier Technology.

SpineMark offers an international medical advisory board and access to SpineMark's network of leading physicians and surgeons across the country. The corporation is an expert in FDA regulations and protocol, offering site operations support and training, contract negotiation and financial management, regulatory and compliance oversight and marketing and media relations.  

For more information on SpineMark CRO Management visit www.spinemarkCRO.com

For more information on Ranier Technology Limited visit

SOURCE SpineMark Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
2. PG500 Series Presented at the AACR Annual Meeting in San Diego
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
7. Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego
8. Solos Endoscopy, Inc. Receives Purchase Orders from University of California, San Diego Medical Center for its MammoView(TM) Product Line
9. California American Water Celebrates No Drugs Down the Drain Week in San Diego
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies